GLAXO.NS - GlaxoSmithkline Pharmaceuticals Limited

NSE - NSE Real Time Price. Currency in INR
2,458.70
-14.55 (-0.59%)
As of 1:34PM IST. Market open.
Stock chart is not supported by your current browser
Previous Close2,473.25
Open2,477.90
Bid2,459.00 x 0
Ask2,460.45 x 0
Day's Range2,455.00 - 2,478.00
52 Week Range2,201.20 - 2,798.50
Volume2,048
Avg. Volume11,896
Market Cap207.38B
BetaN/A
PE Ratio (TTM)61.83
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GSK CEO: Our top priority is to invest in growth in our c...
    CNBC Videos11 days ago

    GSK CEO: Our top priority is to invest in growth in our c...

    Emma Walmsley, GlaxoSmithKlein CEO, speaks to CNBC's Meg Tirrell at the J.P. Morgan Health Care Conference about reshaping the company and her outlook for 2018.

  • SmarterAnalyst2 days ago

    Here’s Why Neurometrix Inc Rose as Much as 60% Today

    Shares of Neurometrix Inc (NASDAQ:NURO) rocketed more than 60% higher at one point Wednesday morning after the healthcare company announced a new collaboration with GlaxoSmithKline plc (ADR) (NYSE:GSK), involving Quell, the company's over-the-counter, 100% drug free chronic pain relief wearable. Specifically, GSK Consumer Healthcare acquires exclusive ownership of Quell technology for markets outside the U.S. Neurometrix will receive a payment of $5 million for the assets relating to Quell technology for markets outside the U.S and up to $21.5 million, upon the achievement of certain development and commercialization milestones. Investors will need to wait to see more precise details, but for a penny stock such as Neurometrix, this is pretty amazing no matter the exact dollar amount.

  • Reuters2 days ago

    Drugmaker GSK cuts back in Africa to hone emerging markets model

    GlaxoSmithKline (GSK.L) is cutting back operations in Africa as its new Chief Executive Emma Walmsley seeks to make the British drugmaker more competitive in emerging markets by ditching her predecessor's expansion plans for the continent. The move, which a GSK spokesman said on Wednesday would result in an unspecified number of job losses in sub-Saharan Africa, follows disappointing sales for many pharmaceutical companies in the region. Five years ago, forecasters predicted annual African drug sales would reach $45 billion by 2020.

  • Reuters2 days ago

    Drugmaker GSK cuts back in Africa to hone emerging markets model

    GlaxoSmithKline is cutting back operations in Africa as its new Chief Executive Emma Walmsley seeks to make the British drugmaker more competitive in emerging markets by ditching her predecessor's expansion plans for the continent. The move, which a GSK spokesman said on Wednesday would result in an unspecified number of job losses in sub-Saharan Africa, follows disappointing sales for many pharmaceutical companies in the region.

  • MarketWatch2 days ago

    NeuroMetrix's stock soars in active trade after collaboration with GlaxoSmithKline on Quell

    Shares of NeuroMetrix Inc. rocketed 78% toward a 7-month high in active premarket trade Wednesday, after chronic pain treatments company announced a collaboration with GlaxoSmithLine PLC involving NeuroMetrix's ...

  • Glaxo CEO Walmsley's Shakeup Continues With Job Cuts in Africa
    Bloomberg2 days ago

    Glaxo CEO Walmsley's Shakeup Continues With Job Cuts in Africa

    GlaxoSmithKline Plc is cutting jobs in Africa and restructuring in more than two dozen countries across the continent, reversing earlier expansion efforts as new Chief Executive Emma Walmsley tries to ...

  • What does GlaxoSmithKline plc’s (LON:GSK) Balance Sheet Tell Us Abouts Its Future?
    Simply Wall St.3 days ago

    What does GlaxoSmithKline plc’s (LON:GSK) Balance Sheet Tell Us Abouts Its Future?

    Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as GlaxoSmithKline plc (LSE:GSK) a safer option. Market participants who are conscious of risk tend toRead More...

  • Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion
    Zacks4 days ago

    Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion

    Glaxo's (GSK) influenza vaccine ??? Fluarix Quadrivalent receives FDA approval for label expansion.

  • Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference
    Zacks7 days ago

    Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference

    Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.

  • Reuters9 days ago

    GSK CEO says looking at Pfizer consumer business, but not a priority

    Pfizer, the largest U.S. drugmaker, said last year it was considering strategic alternatives, including a sale or spinoff, of the consumer business, which had sales of about $3.4 billion in 2016 and could cost more than $15 billion to acquire. "At this stage it would be weird if we didn't look at it," GSK Chief Executive Emma Walmsley said, responding to questions at the JP Morgan Healthcare Conference in San Francisco. Despite her consumer products background, Walmsley repeatedly said that the company's pharmaceuticals business and pharma research and development is GSK's top priority.

  • Reuters9 days ago

    GSK CEO says looking at Pfizer consumer business, but not a priority

    Pfizer, the largest U.S. drugmaker, said last year it was considering strategic alternatives, including a sale or spinoff, of the consumer business, which had sales of about $3.4 billion in 2016 and could cost more than $15 billion to acquire. "At this stage it would be weird if we didn't look at it," GSK Chief Executive Emma Walmsley said, responding to questions at the JP Morgan Healthcare Conference in San Francisco. Despite her consumer products background, Walmsley repeatedly said that the company's pharmaceuticals business and pharma research and development is GSK's top priority.

  • Glaxo Shifts Gears to Fire Up Growth With Rival Astra Closing In
    Bloomberg10 days ago

    Glaxo Shifts Gears to Fire Up Growth With Rival Astra Closing In

    CEO Walmsley has reshuffled 40 percent of top managers to spark innovation

  • What Should We Expect From GlaxoSmithKline plc’s (LON:GSK) Earnings In The Years Ahead?
    Simply Wall St.10 days ago

    What Should We Expect From GlaxoSmithKline plc’s (LON:GSK) Earnings In The Years Ahead?

    GlaxoSmithKline plc’s (LSE:GSK) latest earnings update in September 2017 confirmed that the company faced a immense headwind with earnings falling by -89.17%. Below, I’ve laid out key growth figures onRead More...

  • The Wall Street Journal10 days ago

    Rivals Help Fund Regeneron’s Gene-Sequencing Effort

    Some of the world’s largest pharmaceutical companies are pooling resources to fund an ambitious genetic and medical database aimed at bolstering the search for new drugs.

  • Glaxo CEO Replaced 50 Top Managers in Shakeup to Spur Growth
    Bloomberg10 days ago

    Glaxo CEO Replaced 50 Top Managers in Shakeup to Spur Growth

    GlaxoSmithKline Plc’s new chief executive officer, Emma Walmsley, has revamped the top ranks of the U.K.’s largest drugmaker, replacing about 50 of the top 125 managers since taking over last year.

  • 1 Reason Dynavax Technologies Corporation Stock Soared in 2017
    Motley Fool11 days ago

    1 Reason Dynavax Technologies Corporation Stock Soared in 2017

    Thanks to the FDA approval of its hepatitis B vaccine, Dynavax's shares crushed the broader market in 2017.

  • Spark, Glaxo Gene Therapies Near $1 Million — Still A Bargain?
    Investor's Business Daily15 days ago

    Spark, Glaxo Gene Therapies Near $1 Million — Still A Bargain?

    Spark and GlaxoSmithKline are pricing the world's first approved gene therapies at prices approaching $1 million.

  • U.K. Clears Glaxo's $700,000 ‘Bubble Boy Disease’ Gene Therapy
    Bloomberg16 days ago

    U.K. Clears Glaxo's $700,000 ‘Bubble Boy Disease’ Gene Therapy

    The U.K.’s thrifty health authority has cleared its most expensive medicine ever -- a $700,000 GlaxoSmithKline Plc treatment for an illness known as “bubble-boy disease.” But the overall cost to the country’s ...

  • 3 Top Dividend Stocks With Yields Over 4%
    Motley Fool19 days ago

    3 Top Dividend Stocks With Yields Over 4%

    High-yield stocks have gotten harder to find in the current bull market, but these three should please even the pickiest income investors.

  • Benzinga19 days ago

    Barron's Picks And Pans: Chevron, Corning, GlaxoSmithKline And More

    This weekend's Barron's examines why things may be looking up for one big oil company. Other featured articles offer the prospects for a big drug maker facing stiff competition and a glassmaker that may ...

  • Barrons.com20 days ago

    [$$] Glaxo: Expect a Speedy Recovery

    Advair, the world’s top-selling respiratory drug, will probably face generic competition in the U.S. beginning in 2018. It’s the biggest moneymaker for United Kingdom-based GlaxoSmithKline , whose earnings estimates have been sliding, and whose shares have tumbled since the summer. To see why, look back to Pfizer (PFE) seven years ago, on the eve of Lipitor’s patent expiration.

  • GuruFocus.com22 days ago

    GlaxoSmithKline Is a Massive Bargain

    Wide moat and low price equals deep discounts for investors

  • Market Realist24 days ago

    Measuring Sanofi’s Valuation This December

    For 3Q17, Sanofi reported revenues of 9.05 billion euros—a 4.7% YoY (year-over-year) rise in operating revenues, compared with 9.03 billion in 3Q16.

  • Should You Sell GlaxoSmithKline plc (LON:GSK) At This PE Ratio?
    Simply Wall St.25 days ago

    Should You Sell GlaxoSmithKline plc (LON:GSK) At This PE Ratio?

    GlaxoSmithKline plc (LSE:GSK) is trading with a trailing P/E of 27.2x, which is higher than the industry average of 25.7x. While GSK might seem like a stock to avoid orRead More...

  • Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb
    Motley Fool28 days ago

    Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb

    Which stock wins in a head-to-head match-up between these two big drugmakers?